Menu Search
Equities

Nipro Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5FA:FRA

Nipro Corp

Actions
  • Price (EUR)8.10
  • Today's Change0.05 / 0.62%
  • Shares traded120.00
  • 1 Year change-5.26%
  • Beta0.3414
Data delayed at least 15 minutes, as of Feb 11 2026 07:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.

  • Revenue in JPY (TTM)652.61bn
  • Net income in JPY15.20bn
  • Incorporated1948
  • Employees39.17k
  • Location
    Nipro Corp3-26, Senriokashin-machiSETTSU-SHI 566-8510JapanJPN
  • Phone+81 663106804
  • Fax+81 663717422
  • Websitehttps://www.nipro.co.jp
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		8086:TYO since
announced		Transaction
value
G2/Spryte Holdco LLCAnnounced28 Oct 202528 Oct 2025Announced-3.30%--
Data delayed at least 15 minutes, as of Feb 10 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.